Cormorant Asset Management’s Heron Therapeutics HRTX Stock Holding History

Cormorant Asset Management’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-150,000	Closed	-$3.67M	–	74
2019 Q1	$3.67M	Sell	150,000 -15,682	-9%	-$411K	0.25%	54
2018 Q4	$4.3M	Sell	165,682 -4,318	-3%	-$119K	0.35%	52
2018 Q3	$5.38M	Sell	170,000 -21,108	-11%	-$786K	0.35%	48
2018 Q2	$7.42M	Hold	191,108	–	–	0.55%	44
2018 Q1	$5.28M	Sell	191,108 -8,892	-4%	-$202K	0.39%	39
2017 Q4	$3.62M	Sell	200,000 -370,000	-65%	-$6.03M	0.38%	44
2017 Q3	$9.21M	Hold	570,000	–	–	1.63%	20
2017 Q2	$7.89M	Sell	570,000 -630,000	-53%	-$9.12M	1.31%	24
2017 Q1	$18M	Sell	1,200,000 -751,263	-39%	-$10.4M	2.61%	13
2016 Q4	$25.6M	Buy	1,951,263 +180,000	+10%	+$2.82M	3.45%	9
2016 Q3	$30.5M	Hold	1,771,263	–	–	3.37%	8
2016 Q2	$32M	Buy	1,771,263 +21,263	+1%	+$415K	4.53%	3
2016 Q1	$33.2M	Buy	1,750,000 +64,281	+4%	+$1.27M	5.01%	2
2015 Q4	$45M	Hold	1,685,719	–	–	5.38%	3
2015 Q3	$41.1M	Buy	1,685,719 +245,719	+17%	+$8.19M	6.57%	1
2015 Q2	$44.9M	Buy	1,440,000 +170,000	+13%	+$3.2M	5.97%	2
2015 Q1	$18.5M	Buy	1,270,000 +570,000	+81%	+$6.43M	2.86%	11
2014 Q4	$7.04M	Hold	700,000	–	–	1.09%	27
2014 Q3	$5.83M	Hold	700,000	–	–	1.2%	22
2014 Q2	$8.62M	Buy	+700,000	New	+$8.36M	2.29%	14

Other funds holding HRTX

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Cormorant Asset Management's HRTX Position: Q2 2019 in Review

Cormorant Asset Management sold out of Heron Therapeutics (HRTX) in Q2 2019, closing a stake of 150,000 shares — an estimated $3.67M sold.

Cormorant Asset Management first reported a position in HRTX in Q2 2014 and held it in 20 quarters. The position peaked at $45M in Q4 2015. 176 funds tracked by Wall St. Rank hold HRTX as of Q2 2019.

Cormorant Asset Management reported no remaining Heron Therapeutics position as of Q2 2019 after selling out during the quarter.
Cormorant Asset Management sold 150,000 Heron Therapeutics shares in Q2 2019, an estimated $3.67M.
Cormorant Asset Management first reported a position in Heron Therapeutics in Q2 2014 and held it in 20 quarters.
Cormorant Asset Management's Heron Therapeutics position peaked at $45M in Q4 2015.
176 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2019.

Based on Cormorant Asset Management's 13F filing for Q2 2019, filed 14 Aug 2019.